BioNano Genomics Appoints Dr. Fahim Amini As Vice President Commercial Operations EMEA
Experienced Genomics Executive to Support Commercial Expansion in Europe and Beyond
SAN DIEGO, May 31, 2013 /PRNewswire/ — BioNano Genomics, the developer of the Irys(TM) System for genome mapping, announced today the appointment of Fahim Amini, Ph.D. as vice president, Commercial Operations EMEA. Dr. Amini will further expand BioNano’s commercial reach for the Irys System, making it possible for researchers and clinicians in Europe, Middle East and Africa to access BioNano’s recently launched Irys platform.
“As we prepare to expand access to the Irys System globally into Europe and beyond, we are looking forward to meeting the needs of researchers and clinicians who require deeper insights into genome variations,” said Todd Dickinson, Ph.D., vice president, Global Commercial Operations. “Fahim’s addition to the team at BioNano Genomics is a key component of our commercial roll-out in Europe. Fahim has a proven track record in supporting labs in Europe, big and small, in the successful adoption of new platforms for genome analysis.”
“This is an exciting time in genomics research, especially with a commercial system that will propel the field of genomics, with all its tremendous advances in the recent years, to the next level,” said Dr. Amini. “It is widely known that detecting structural variation and penetrating difficult repetitive regions with today’s short and medium-read technologies has been challenging. By preserving the native genomic structure, the Irys System allows new insights to be gained through direct visualization of genome structure, enabling the detection of structural variation, significantly improving genome assemblies, phasing haplotypes, and many other applications yet to be developed. I am eager to help researchers and clinicians throughout Europe, Middle East and Africa access BioNano’s breakthrough genome mapping solution to drive new discoveries.”
Dr. Amini was most recently director of EMEA at Complete Genomics, where he was responsible for sustainable growth of CGI revenue and support structure. Before Complete Genomics, he held several commercial roles of increasing scope and responsibility at Illumina, and prior to that, at Affymetrix. He received his Ph.D. in biological sciences and his BSc with honors in microbiology and microbial technology from the University of Warwick, Coventry.
BioNano Genomics will be at the European Human Genetics Conference 2013 presented by the European Society of Human Genetics (ESHG) taking place in Paris from June 8 to 11. In addition, Pui-Yan Kwok, M.D., Ph.D., Henry Bachrach Distinguished Professor at the UCSF School of Medicine, will be giving a podium presentation on genome-wide structural variation analysis and de novo sequence assembly at ESHG on June 9(th) at 1:15 pm in the Grand AmphithÃ©atre.
Irys makes it possible to routinely and accurately detect genomic structural variation and to finish genome assemblies. The fully automated Irys benchtop instrument uses the IrysChip to uncoil and confine long DNA molecules in proprietary Nanochannel Arrays(TM) where they are uniformly linearized in a highly parallel display for high-resolution, single-molecule imaging. Irys does not employ DNA fragmentation or amplification, which are typical with next-generation sequencing. The result is sequence information over extremely long “reads” ranging from hundreds of kilobases to a megabase, where the sample’s valuable structural information is preserved. Irys makes it possible for researchers to directly observe structural variants including replications, deletions, translocations and inversions.
About BioNano Genomics
Headquartered in San Diego, BioNano Genomics is delivering an altogether better way of gaining a fully informed understanding of genomes. The Company’s platform provides researchers and clinicians the most comprehensive, organized and actionable picture of a genome with unprecedented insights into how the individual components of genomes are ordered, arranged, and interact with each other. BioNano Genomics works with institutions in life science, translational research, molecular diagnostics and personalized medicine. The Company is supported by private investors and grant funding from genomics programs at federal agencies, including the NIH and NIST-ATP.
Notes: BioNano Genomics is a trademark of BioNano Genomics, Inc. Any other names of actual companies, organizations, entities, products or services may be the trademarks of their respective owners.
SOURCE BioNano Genomics